Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein. Svilenov HL, Sacherl J, Reiter A, Wolff LS, et al. Antiviral Res 2021 Nov 10:105197. doi: 10.1016/j.antiviral.2021.105197.

Read + Share

Amedeo Smart

Independent Medical Education

Svilenov HL, Sacherl J, Reiter A, Wolff LS, et al. Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein. Antiviral Res 2021 Nov 10:105197. doi: 10.1016/j.antiviral.2021.105197.
PMID: 34774603